Get startedLog in
    Picture of Integra LifeSciences Holdings logo

    IART — Integra LifeSciences Holdings Cashflow Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedMid CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Integra LifeSciences Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:10-K10-K10-K10-K10-K
    Standards:
    USG
    USG
    USG
    USG
    USG
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line13416918167.7-6.94
    Depreciation
    Deferred Taxes
    Non-Cash Items59.48.119.6342.247.2
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital-41.318.2-39.4-81.6-31
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Other Assets
    Change in Accounts Payable
    Change in Payable / Accrued Expenses
    Change in Other Liabilities
    Cash from Operating Activities204312264140129
    Capital Expenditures-63.9-48.1-47.1-66.9-114
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-4.18-113-11.5-27.3-276
    Acquisition of Business
    Sale of Business
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Change in Net Investments
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities-68.1-161-58.6-94.2-391
    Financing Cash Flow Items-29.4-5.05-24.6-13.7-15.4
    Other Financing Cash Flow
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities122-98.2-252-230238
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash27143.3-56.8-180-30